Tourette syndrome and other tic disorders of childhood

Nilles, Christelle; Hartmann, Andreas; Roze, Emmanuel; Martino, Davide; Pringsheim, Tamara

doi:10.1016/b978-0-323-98817-9.00002-8

Cited by 5 publications

(1 citation statement)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TS often develops in association with a variety of neuropsychiatric diseases, such as attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), anxiety, emotional disorder, destructive behavior, learning difficulties and sleep disorders [ 1 , 2 ]. The most common comorbidity was ADHD, while the second most common comorbidity in TS was OCD, diagnosed in 50% of cases of TS in the already mentioned largest service-based study to date [ 3 ]. The average prevalence of ADHD in TS patients is about 50%–60% (33%–91%), with a higher prevalence in males [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Clonidine Patch for Tourette Syndrome With Attention-Deficit/Hyperactivity Disorder

Chen,

Ke,

Ouyang

et al. 2024

Psychiatry Investig

View full text Add to dashboard Cite

Objective To explore the efficacy and safety of clonidine adhesive patch in Tourette syndrome (TS) patients with comorbid attentiondeficit/hyperactivity disorder (ADHD).Methods This study was conducted on a sample of children and adolescents with TS who had comorbid ADHD between May 2012 and March 2015. The patients were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, and were randomly assigned to four different dose groups: 1.0 mg/week, 1.5 mg/week, 2.0 mg/week and placebo group, and the symptom was evaluated by Swanson, Nolan, and Pelham Rating Scale, Version IV (SNAP-IV) and Yale Global Tic Severity Scale scales every 2 weeks. The primary outcome was tic disorders (TD) effective rate at week 8.Results One hundred and twenty-seven TS patients with comorbid ADHD in 2.0 mg/week (n=35), 1.5 mg/week (n=27), 1.0 mg/week (n=36) and placebo groups (n=29) were included in this subgroup analysis. The TD effective rate of the 2.0 mg, 1.5 mg, and 1.0 mg groups at week 8 were significantly better than that in placebo group (85.7%, 81.5%, and 86.1% vs. 20.7%, all p<0.0001). All groups demonstrated significant improvements in SNAP-IV total scale scores compared to baseline (p=0.0004), with treatment groups showing only a trend for better performance compared to placebo group at week 8, without statistical differences (22.1±15.41, 21.3±11.96, and 21.2±12.48 vs. 26.0±13.37, p=0.3385). A total of 9 adverse reactions occurred, all recovered spontaneously without additional medication.Conclusion Clonidine adhesive patch could safely and effectively reduce the tic symptoms of TS patients with comorbid ADHD, and might be potentially helpful in the ADHD symptoms control.

show abstract